Highest-materiality recent filing
Orly Mishan elected with 11,930,745 votes for, 1,396,139 withheld; Sean Salmon elected with 13,322,425 for, 4,459 withheld.
Adagio Medical receives Nasdaq notice for bid price < $1; 180-day cure period until Dec 9, 2026
Notice from Nasdaq on June 12, 2026 for non-compliance with Listing Rule 5550(a)(2) (min $1 bid).
Adagio submits PMA to FDA for vCLAS VT ablation system; trial shows 97.4% acute success
PMA application for vCLAS Ventricular Ablation System to treat drug-refractory VT in structural heart disease.
Net loss of $7.0M for Q1 2026 vs $7.7M in Q1 2025; no revenue; R&D expense $2.7M, SG&A $2.5M.
Adagio Medical reports positive pivotal vCLAS ventricular ablation trial results
84% freedom from ICD shock and 59% freedom from VT recurrence at 6 months in FULCRUM-VT study.
Adagio Medical sets 2026 annual meeting for June 16; deadlines for proposals
Annual meeting date: June 16, 2026.
Adagio Medical receives FDA IDE approval to study next-gen vCLAS ventricular ablation system
FDA grants IDE approval to expand FULCRUM-VT trial for next-gen vCLAS ULTA Ventricular Ablation System treating SMVT.
Net loss of $25.1M for FY2025, down from $75.0M in FY2024; Q4 net loss $3.3M vs $57.4M.
Adagio Medical annual meeting elects directors Usen and Cox, ratifies auditor
Todd Usen elected with 12,915,589 votes for and 19,972 withheld; James L. Cox, M.D. elected with 11,610,366 for and 1,325,195 withheld.
Adagio Medical expands board to seven, appoints former Medtronic EVP Sean Salmon
Board increased from six to seven directors; Salmon appointed Class II director, term expiring at 2026 annual meeting.
Adagio Medical Q3 net loss $10.1M vs $4.6M; completes 209-patient VT trial, closes $50M placement
Net loss of $10.1M in Q3 2025, vs $4.6M in Q3 2024; cash $4.7M as of Sep 30, 2025.
Adagio Medical sets 2025 Annual Meeting for Dec 15; record Oct 31, proposal deadline Nov 3
Annual Meeting will be held December 15, 2025; record date is October 31, 2025.
Adagio Medical closes $19M private placement to fund VT ablation device and FDA submission
Closed $19M upfront private placement led by existing and new healthcare institutional investors.
Adagio Medical (ADGM) announces $19M upfront, $31M potential warrant proceeds in private placement
Upfront proceeds ~$19M from 9.79M shares/pre-funded warrants at $1.9403 combined; Perceptive Advisors affiliate invests $4.25M.
Adagio Medical reports 97.4% acute effectiveness in FULCRUM-VT pivotal study for VT ablation
207 patients enrolled at 19 U.S./Canadian sites; 97.4% acute clinical success (non-inducibility of target VTs).
Adagio completes enrollment in FULCRUM-VT pivotal IDE study for vCLAS cryoablation system
Enrolled 208 patients across 20 U.S. and Canadian centers for vCLAS System to treat monomorphic ventricular tachycardia.
Adagio Medical appoints Deborah Kaster as CFO, replacing interim CFO Dan George
Deborah Kaster, previously CBO, becomes CFO effective September 5, 2025; Daniel George steps down as interim CFO.
Adagio Medical Q2 2025 net loss $3.9M; FULCRUM-VT enrollment at 85%
Net loss narrowed to $3.9M ($0.26 basic EPS) from $5.7M in Q2 2024; revenue figure not disclosed.
Adagio Medical Q1 net loss $7.7M; FDA breakthrough device designation
Net loss of $7.7M ($0.50 per share) vs $8.0M ($10.28 per share) in Q1 2024.
Adagio Medical appoints Daniel George as Interim CFO effective April 17, 2025
Daniel George appointed Interim CFO, principal financial and accounting officer.
Adagio Medical reports FY2024 revenue up 101% to $0.6M, net loss widens to $75M, appoints CBO
Full year revenue $0.6M (+101% YoY); net loss $75.0M vs $36.6M prior year, driven by $49.2M impairment charge.
CFO John Dahldorf resigns; FULCRUM-VT trial enrollment exceeds 40%
CFO John Dahldorf resigns effective March 21, 2025, no dispute over accounting; transitional CFO to be named.
Adagio Medical COO Hakon Bergheim departs in corporate restructuring
Hakon Bergheim, Chief Operating Officer, departed effective February 28, 2025.
Adagio Medical restructures to focus on US pivotal IDE trial; reduces workforce
Pauses limited European launch of vCLAS catheter; redirects resources to US FULCRUM-VT Pivotal IDE trial (over 35% enrolled).
Notice of termination sent Jan 30, 2025; agreement terminates July 30, 2025 (180 days from Jan 31).
Adagio Medical enters waiver for defaults, receives Nasdaq non-compliance letter
Issued 183,333 restricted shares at $2.00 per share to settle registration delay payments with buyers.
Director resigns; Adagio Medical to be non-compliant with Nasdaq audit committee rule
Shahram Moaddeb resigns as director effective Jan 1, 2025, citing demands of other business ventures; no dispute with company.
Adagio Medical appoints Todd Usen as CEO; founder Olav Bergheim departs as CEO and Chairman
Olav Bergheim resigns as CEO and Chairman effective Dec 13, 2024; receives severance of $1.2M cash plus contingent $300K.
Adagio Medical Q3 2024 revenue $185K (+351% YoY); net loss $4.6M; CMS coverage secured
Revenue of $185K in Q3 2024, up 351% from $41K in Q3 2023.
Restatement corrects double-counting of accrued interest on convertible notes; net loss for 2023 reduced by $1.556M to $36.590M.
Audit committee concluded FY2023 audited and Q1/Q2 2024 unaudited statements should not be relied upon due to accrued interest misstatement.
Adagio Medical obtains CE Mark for VT catheter, closes business combination with $35M pro forma cash
CE Mark approval and commercial launch of vCLAS catheter for ventricular tachycardia in select European markets.
Adagio Medical closes SPAC merger with $84.2M in financing; reports H1 2024 net loss of $14.5M
Business combination with ARYA Sciences Acquisition Corp IV closed on July 31, 2024, providing ~$84.2 million in financing.
Adagio Medical completes de-SPAC merger with ARYA, begins trading as ADGM on Nasdaq
Post-combination, 13,387,636 shares of New Adagio common stock outstanding; 7,587 shares under options.
On April 17, 2025, Adagio Medical Holdings, Inc. (the “Company”) appointed Daniel George as the Company’s Interim Chief Financial Officer and designated Mr. George as its principal financial officer and principal accounting officer.
On March 11, 2025, John Dahldorf, the Chief Financial Officer of Adagio Medical Holdings, Inc. (the “Company”) announced his decision to resign as Chief Financial Officer, effective March 21, 2025.
As part of its corporate restructuring announced on February 28, 2025, Adagio Medical Holdings, Inc. (the “Company”), announced the departure of Hakon Bergheim, the Company’s Chief Operating Officer, effective February 28, 2025.
Hakon Bergheim 42 Chief Operating Officer
Olav Bergheim 74 Chief Executive Officer and Chairman
Olav Bergheim and James L. Cox were appointed as Class I directors
Keyvan Mirsaeedi-Farahani, Timothy Moran and Sandra Gardiner were appointed as Class III directors
Orly Mishan and Shahram Moaddeb were appointed as Class II directors
Olav Bergheim and James L. Cox were appointed as Class I directors
Orly Mishan and Shahram Moaddeb were appointed as Class II directors
Keyvan Mirsaeedi-Farahani, Timothy Moran and Sandra Gardiner were appointed as Class III directors
John Dahldorf 68 Chief Financial Officer
Max materiality 0.85 · Median 0.68 · Most common event other_material